Brief: Karyopharm Announces Clinical Trial Collaboration With Bristol Myers Squibb
30/10/2023 12:15
Oct 30 (Reuters) - Bristol-Myers Squibb Co BMY.N :
* KARYOPHARM ANNOUNCES CLINICAL TRIAL COLLABORATION WITH
BRISTOL
MYERS SQUIBB TO EVALUATE NOVEL CELMOD™ AGENT CC- 92480
MEZIGDOMIDE IN COMBINATION WITH SELINEXOR IN PATIENTS WITH
RELAPSED/REFRACTORY MULTIPLE MYELOMA
* KARYOPHARM THERAPEUTICS INC- PHASE 1B/2 TRIAL TO
INVESTIGATE
MEZIGDOMIDE IN COMBINATION WITH SELINEXOR EXPECTED TO BE
INITIATED 1H 2024
Source text for Eikon: ID:nPn3qgfhfa
Further company coverage: BMY.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Karyopharm Therapeutics
See all newsBrief: Karyopharm Therapeutics - Enters Forbearance Agreement And Waiver On Sept 10, 2026 - SEC Filing
Brief: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Karyopharm Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Karyopharm Q2 revenue falls as license revenue drops; expects funds to last into September
Karyopharm Therapeutics Inc. expected to post a loss of $1.28 a share - Earnings Preview